Alvesco

Alvesco is a brand name of ciclesonide, approved by the FDA in the following formulation(s):

ALVESCO (ciclesonide - aerosol, metered; inhalation)

• 
  Manufacturer: NYCOMED US
  
  Approval date: January 10, 2008
  
  Strength(s): 0.08MG/INH, 0.16MG/INH ^[RLD]

Has a generic version of Alvesco been approved?

No. There is currently no therapeutically equivalent version of Alvesco available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alvesco. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
  Patent 5,482,934
  Issued: January 9, 1996
  Inventor(s): Calatayud; Jose & Conde; Jose R. & Luna; Manuel
  Assignee(s): Especialidades Latinas Medicamentos Universales, S.A. (Elmu, S.A.)
  The present invention relates to compounds of the formula: ##STR1## in which X.sub.1 and X.sub.2 correspond to H or F without distinction; R.sub.1 represents the following radicals: ##STR2## and R.sub.2 represents the radicals ##STR3## in the form of an R epimer, an S epimer, or a stereoisomeric mixture of the R and S epimers in terms of the orientation of the substituents on the carbon atom at position 22, novel intermediates and a method of their preparation by hydrolysis-ketalization, and use of such compounds as drugs and/or therapeutic agents.
  
  Patent expiration dates:
  
  
  • October 24, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING INFLAMMATORY CONDITIONS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Medicinal aerosol formulations
  Patent 5,605,674
  Issued: February 25, 1997
  Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
  Assignee(s): Riker Laboratories, Inc.
  A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
  
  Patent expiration dates:
  
  
  • February 25, 2014
    
    ✓ 
    Drug product
  
  



• 
  Medicinal aerosol formulations
  Patent 5,683,677
  Issued: November 4, 1997
  Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
  Assignee(s): Riker Laboratories, Inc.
  A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
  
  Patent expiration dates:
  
  
  • November 4, 2014
    
    ✓ 
    Drug product
  
  



• 
  Seal configuration for aerosol canister
  Patent 5,775,321
  Issued: July 7, 1998
  Inventor(s): Alband; Todd D.
  Assignee(s): Minnesota Mining and Manufacturing Company
  A dual seal configuration for an aerosol canister containing a medicinal aerosol formulation. The canister includes a vial body and valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation. The dual seal configuration reduces leakage of contents, and is particularly helpful where the formulation includes hydrofluorocarbon propellant and an ethanol cosolvent. The first seal can be selected to be a barrier to the formulation components, while the second seal can be relatively more labile to such components.
  
  Patent expiration dates:
  
  
  • July 7, 2015
    
    ✓ 
    Drug product
  
  



• 
  Device for delivering an aerosol
  Patent 6,006,745
  Issued: December 28, 1999
  Inventor(s): Marecki; Paul E.
  Assignee(s): Minnesota Mining and Manufacturing Company
  A device for delivering an aerosol comprises a casing member, a valve stem, and a sealing member, wherein the sealing member comprises a thermoplastic elastomer comprising of a copolymer of about 80-95 mole % ethylene and about 5-20 mole % of at least one comonomer wherein the comonomer(s) are 1-butene, 1-hexene, or 1-octene. The device is used with pharmaceutical formulations containing 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane as the propellant.
  
  Patent expiration dates:
  
  
  • December 28, 2016
    
    ✓ 
    Drug product
  
  



• 
  Seal configuration for aerosol canister
  Patent 6,036,942
  Issued: March 14, 2000
  Inventor(s): Alband; Todd D.
  Assignee(s): 3M Innovative Properties Company
  An aerosol canister for containing a medicinal aerosol formulation. The canister involves a vial body and a valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation.
  
  Patent expiration dates:
  
  
  • April 30, 2013
    
    ✓ 
    Drug product
  
  



• 
  Medicinal aerosol products containing formulations of ciclesonide and related steroids
  Patent 6,120,752
  Issued: September 19, 2000
  Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
  Assignee(s): 3M Innovative Properties Company
  Byk Gulden Lomberg Chemische Fabrik GmbH
  A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
  
  Patent expiration dates:
  
  
  • May 13, 2018
    
    ✓ 
    Drug product
  
  



• 
  Medicinal aerosol formulation of ciclesonide and related compounds
  Patent 6,264,923
  Issued: July 24, 2001
  Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
  Assignee(s): 3M Innovative Properties Company
  A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
  
  Patent expiration dates:
  
  
  • May 13, 2018
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 10, 2011 - NEW DOSAGE FORM
  
  
  • October 20, 2011 - NEW CHEMICAL ENTITY
  
  

See also...

• Alvesco Consumer Information (Drugs.com)
• Alvesco Aerosol Consumer Information (Wolters Kluwer)
• Alvesco HFA inhalation Consumer Information (Cerner Multum)
• Alvesco inhalation Consumer Information (Cerner Multum)
• Alvesco Advanced Consumer Information (Micromedex)
• Ciclesonide Aerosol Consumer Information (Wolters Kluwer)
• Ciclesonide inhalation Consumer Information (Cerner Multum)
• Ciclesonide Inhalation Advanced Consumer Information (Micromedex)